Document Detail

Pathways in pulmonary arterial hypertension: the future is here.
MedLine Citation:
PMID:  23204120     Owner:  NLM     Status:  In-Data-Review    
It is well established that the endothelin, nitric oxide and prostacyclin pathways play an important role in the development of pulmonary arterial hypertension (PAH). Indeed, the therapeutic options currently available for the management of PAH all act on one of these mechanistic pathways. However, this is an exciting time for both clinicians and scientists, as increased understanding of the mechanisms involved in the pathogenesis and progression of PAH has resulted in the development of a number of novel therapeutic options. This article highlights how the introduction of new compounds such as macitentan, riociguat and selexipag, which act on the endothelin, nitric oxide and prostacyclin pathways, respectively, have the potential to further improve the prognosis for patients with PAH.
Olivier Sitbon; Nicholasw Morrell
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European respiratory review : an official journal of the European Respiratory Society     Volume:  21     ISSN:  1600-0617     ISO Abbreviation:  Eur Respir Rev     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111391     Medline TA:  Eur Respir Rev     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  321-7     Citation Subset:  IM    
Université Paris-Sud, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. # Dept of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Challenges in the diagnosis and treatment of pulmonary arterial hypertension.
Next Document:  Pulmonary arterial hypertension associated with congenital heart disease.